FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1897-1898 June 30, 1994 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Currently, patients with ulcerative colitis or Crohn's disease are treated sequentially with 5-aminosalicylic acid preparations, corticosteroids, and mercaptopurine or azathioprine; metronidazole is beneficial in patients with colonic or perianal Crohn's disease. New systems to deliver 5-aminosalicylic acid are useful in patients with Crohn's disease of the small intestine and eliminate sulfapyridine-associated toxicity, but they are not more effective than sulfasalazine for colonic inflammation. Mercaptopurine and azathioprine are effective in patients with steroid-dependent or unresponsive Crohn's disease, but a three-month delay in response limits their use in acutely ill patients.

The medical community and patients with inflammatory bowel disease have eagerly . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Wyllie, R., Sarigol, S. (1998). The Treatment of Inflammatory Bowel Disease in Children. CLIN PEDIATR 37: 421-425  
• Aiko, S., Conner, E. M., Fuseler, J. A., Grisham, M. B. (1997). Effects of Cyclosporine or FK506 in Chronic Colitis. J. Pharmacol. Exp. Ther. 280: 1075-1084 [Abstract] [Full Text]